Cancer Targeting Systems
Cambridge
About Cancer Targeting Systems
Cancer Targeting Systems (CTS) is developing a new non-viral, gene therapy-based approach for the treatment of cancer. Nanoparticles are administered systemically, distribute throughout the patient’s body and address metastatic tumours. Gene expression of a therapeutic payload is cancer cell specific, and triggers local activation of the immune system, leading to cancer cell destruction.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.9M
- Last round: Series Unknown (Sep 2014)
- Website: cts-bioscience.com
- Phone: +44 1799 531 130
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/cancer-targeting-systems-2092397 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.